Printer Friendly

Profiting from Biotech Stocks: New Book from Avance Helps Investors to Pick Biotech Stocks.

BASEL, Switzerland -- Have you ever asked yourself why you haven't been the one to invest in a biotech stock that soared 50% in a single day? Biotech stocks, of course, promise enormous profits, but carry huge downside risks.

A new book "Valuation in Life Sciences: A Practical Guide" leads readers step by step through the theory of life science valuation. Published by Springer Verlag, it is an important read for biotech investors. The book will be available in February in all major bookstores.

It is the first book of its kind that combines industry data and valuation theory together with practical advice. It includes valuation techniques and tools that allow investors to pick undervalued biotech stocks.

"If you're going to invest in biotech, you must understand the business model and how scientific results affect share price," says Boris Bogdan, MD and co-author.

Ralph Villiger, mathematician and co-author, adds that it is only possible to spot undervalued shares once you know how to quantify news on clinical successes, license agreements and M&A activity.

The authors, partners of Avance, advise banks and funds on investments in the life science industry.

About Avance

Avance is a Swiss consulting boutique, headquartered in Basel, Switzerland. The company, specialised in valuation for the life science industry, has an international client base in the financial and life science sectors. The company aims to establish new standards in licensing, M&A and investing to enable customers to reach optimal decisions. (
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 8, 2007
Previous Article:Obtain Comprehensive Data and Analysis of the Construction Materials Market in Germany.
Next Article:VentureNet Capital Group will Attend the 19th Annual Roth Capital Partners Conference.

Related Articles
Tech stocks get hot.
Betting on biotechnology: biotech funds may have a bright future ahead in spite of a down 2001. (Mutual Fund Focus).
Biotech balance: mutual fund diversification lets investors temper biotech's risk.
Lab results: hot issues in biotech & life sciences.
Many healthy returns: healthcare funds may be the right prescription for long-term stock market success.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters